Contact us
Contact us

Case study

HeartMonitoringAI. Predicting heart failure using non-invasive intracardiac pressure monitoring and artificial intelligence methods

Challege

The goal of the project is to improve a state-of-the-art cardiac monitoring device that allows non-invasive measurement of mean pulmonary artery pressure (mPAP).

Share:

Organisation profile

Acorai, based in Helsingborg, provides heart failure management through non-invasive intracardiac pressure monitoring.

Acorai was founded in 2019 and is headquartered in Skane, Sweden. Acorai is developing the next heart failure vital sign tool to improve standard of care for heart failure patients. Acorai is developing a device for heart failure management through non-invasive intracardiac pressure monitoring (ICPM), to help reduce hospitalizations and readmissions. Their product, The Acorai Heart Monitor, can monitor mean pulmonary artery pressure (mPAP) non-invasively through a machine learning analysis of pressure dynamics in acoustics, vibratory and waveform data. 

Solution

The goal of the project is to improve a state-of-the-art cardiac monitoring device that allows non-invasive measurement of mean pulmonary artery pressure (mPAP).

The solution will allow the device to be used more widely. The project will develop a new assembly solution for the device and develop advanced machine learning models that will predict 30-180 day patient outcomes (e.g., hospitalization and/or death). This will allow for more personalized and effective treatment of heart failure patients.

Solutions applied in the project:

  • Improving the device’s attachment to the patient’s body: The structure of the existing device will be changed to more comfortably stick to the patient’s body for longer periods of time.
    The changes will be slightly adjusted to accommodate gender and different body types. In addition, the device will be equipped with adjustable straps to hold it in place without user support. Clinical studies will also be conducted on the need for potential adhesives on the device to increase comfort and help maintain the device’s position.
  • Improve software by building a system that analyzes patients’ medical records and links them to device output to predict adverse events, hospitalization risk and mortality risk

This project will enable Acorai, the Leader and developer of the device, to significantly increase the usability of the product, both in terms of improved hardware and improved software features. To us, it will enable the company to improve its tools for medical records and transfer them from the Polish market to the global market.

MIM Solutions will participate in the software part of the project. The work will take place as part of industrial research and development.

International consortium partners:

Acorai AB (SWE)

MIM Solutions' main tasks as a project consortium member:

  • Creation of AI / Machine Learning models that will predict a patient’s prognosis for 30-180 days based on the measurement device data and additional medical record data, including:
    • risk of side effects 
    • likelihood of hospitalization
    • likelihood of death
  • Create a way to preprocess cardiac data. The data processed will be data obtained by the Acorai device (phonocardiography, photoplethysmography, seismocardiography, ECG, RRI, heart rate) and patient medical records.

Results

As a result of the project, MIM Solutions will obtain ownership rights to libraries and tools for creating predictive models, as well as libraries and tools for testing and validating models.

Contract number: InnovativeSMEs/2/96/HeartMonitoringAI/2022 

Project Number: Predicting heart failure using non-invasive intracardiac pressure monitoring and artificial intelligence methods [HeartMonitoringAI] selected under the Innovative SMEs partnership (Eurostars 3 – Call 2)

Related Customer stories

Our work in AI is a tangible result of our team's commitment to research and development.

Recommendation system for the optimal hormone stimulation protocol.

Creating a recommendation system for the optimal hormonal stimulation protocol based on DNA polymorphisms and relations between specific polymorphisms and other data.

Deep neural network based system generating medical documentation

Deep neural network based system generating medical documentation abstracts and voicebot-performed medical interviews abstracts supporting medical diagnostics during medical consultancy.

An intelligent platform supporting the diagnosis of fertility disorders

For over 20 years INVICTA sp. z o.o. has specialized in comprehensive fertility support and treatment of fertility disorders, creating pioneering solutions and providing access to the most modern diagnostic tests.
View all Customer stories

Get in touch

MIM AI can help develop AI in your company, please contact us and we’ll talk you through it.